Skip to main content
SpringerLink
Log in

Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

Combination of sacubitril, a novel neprilysin inhibitor, with valsartan, an angiotensin receptor blocker, was approved by FDA as first line treatment of chronic heart failure resulting from hypertension. A selective, rapid, accurate and precise stability indicating RP-HPLC method was developed for the estimation of sacubitril and valsartan in the presence of their impurities in bulk powder and pharmaceutical dosage form. Experimental design using face-centered composite design was applied during method optimization to achieve best resolution with minimum experimental trials. The two independent variables were buffer pH and organic modifier volume in the mobile phase. Chromatographic separation was accomplished using a Zorbax Eclipse C18 Cyano column (150 mm, 4.6 mm, 5 µm) and a mobile phase composed of ammonium acetate buffer (0.02 M, adjusted to pH 4 with acetic acid): acetonitrile (55:45, v/v) at a flow rate 1 mL min−1. Detection was performed at 254 nm. Sharp and well-resolved peaks for sacubitril and valsartan were obtained with retention times 4.91 and 2.53 min, respectively. A complete forced degradation of sacubitril was achieved and degradation kinetics under basic conditions was studied and was found to follow first-order kinetics. Structure elucidation was performed using mass spectrometry. The method was fully validated in terms of selectivity, linearity, accuracy, precision and robustness in agreement with ICH guidelines Q2 (R1).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJV (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380(9851):1387–1395. doi:10.1016/S0140-6736(12)61227-6

    Article  CAS  PubMed  Google Scholar 

  2. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual acting angiotensin receptor—neprilysin inhibitor (ARNi). J Clin Pharmcol 50(4):401–414. doi:10.1177/0091270009343932

    Article  CAS  Google Scholar 

  3. de Bold AJ (2011) Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can J Physiol Pharm 89(8):527–531. doi:10.1139/y11-019

    Article  CAS  Google Scholar 

  4. Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, Akahori M, Zhang J (2015) Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res 38(4):269–275. doi:10.1038/hr.2015.1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thürmann PA (2000) Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 1(2):337–350. doi:10.1517/14656566.1.2.337

    Article  PubMed  Google Scholar 

  6. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, Gasparo M (1995) Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Ther 13(3):230–250. doi:10.1111/j.1527-3466.1995.tb00305.x

    Article  CAS  Google Scholar 

  7. Vardeny O, Miller R, Solomon SD (2014) Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2(6):663–670. doi:10.1016/j.jchf.2014.09.001

    Article  PubMed  Google Scholar 

  8. Vilela-Martin JF (2016) Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Des Dev Ther 10:1627

    Article  CAS  Google Scholar 

  9. Chunduri RH, Dannana GS (2016) Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 30(9):1467–1475. doi:10.1002/bmc.3707

    Article  CAS  PubMed  Google Scholar 

  10. Patel KH, Luhar SV, Narkhede SB (2016) Simultaneous estimation of sacubitril and valsartan in the synthetic mixture by RP-HPLC method. J Pharm Sci Biosci Res 6(3):262–269

    Google Scholar 

  11. Naazneen S, Sridevi A (2017) Development of assay method and forced degradation study of valsartan and sacubitril by RP-HPLC in tablet formulation. Int J App Pharm 9(1):9–15

    CAS  Google Scholar 

  12. Miller JN, Miller JC (2010) Statistics and chemometrics for analytical chemistry, 6th edn. Pearson education Limited, England, pp 186–216

    Google Scholar 

  13. Deming SN, Morgan SL (1993) Experimental design: a chemometric approach, 2nd edn. Elsevier Publishers, Amsterdam, pp 151–169 (227–274)

    Google Scholar 

  14. Entresto-Novartis Pharmaceuticals Corporation (2015) Highlights of prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf. Accessed 22 Apr 2017

  15. Minitab®, Version 17, Statistical Software; Minitab, Inc.: State College, PA, USA, 2014. (2014). Version 17 edn, State College, PA, USA

  16. El-Zaher AA, Mahrouse MA (2013) A validated spectrofluorimetric method for the determination of nifuroxazide through coumarin formation using experimental design. Chem Cent J 7(1):1–12. doi:10.1186/1752-153X-7-90

    Article  CAS  Google Scholar 

  17. El-Zaher AA, Mahrouse MA (2013) Utility of experimental design in pre-column derivatization for the analysis of tobramycin by HPLC—fluorescence detection: application to ophthalmic solution and human plasma. Anal Chem Insights 8:9–20. doi:10.4137/ACI.S11612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Commission of the European Communities (1996) Q2 (R1) Validation of analytical procedures: text and methodology. In: Proceedings of the international conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use, Geneva (incorporated in 2005)

  19. Khamanga SM, Walker RB (2011) The use of experimental design in the development of an HPLC–ECD method for the analysis of captopril. Talanta 83(3):1037–1049. doi:10.1016/j.talanta.2010.11.025

    Article  CAS  PubMed  Google Scholar 

  20. The United States Pharmacopeia (USP 34), National Formulary (NF 29), 20011, Rockville, MD

  21. Montgomery DC (2008) Design and analysis of experiments, 7th edn. John Wiley & Sons Inc, Asia, pp 1–22 (60–114, 207–263)

    Google Scholar 

  22. Blessy M, Patel RD, Prajapati PN, Agrawal YK (2014) Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 4(3):159–165. doi:10.1016/j.jpha.2013.09.003

    Article  CAS  PubMed  Google Scholar 

  23. Bruckner R (2001) Advanced organic chemistry: reaction mechanisms, 1st edn. Academic press, San Diego

    Google Scholar 

  24. Sudesh BM, Uttamrao KS (2009) Determination and validation of valsartan and its degradation products by isocratic HPLC. J Chem Metrol 3(1):1–12

    CAS  Google Scholar 

  25. Berry RS, Rice SA, Ross J (2001) Physical and chemical kinetics, 2nd edn. Oxford University Press, Oxford

    Google Scholar 

  26. Upadhyay SK (2007) Chemical kinetics and reaction dynamics, 1st edn. Springer, Amsterdam. doi:10.1007/978-1-4020-4547-9

  27. Wright MR (2004) Introduction to chemical kinetics. Chichester, UK

    Book  Google Scholar 

  28. Drug stability and kinetics. https://www.scribd.com/doc/76640703/Drug-Stability-and-Kinetics. Accessed 29 March 2017

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt

    Bahia A. Moussa, Hanaa M. A. Hashem, Marianne A. Mahrouse & Sally T. Mahmoud

Authors
  1. Bahia A. Moussa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanaa M. A. Hashem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianne A. Mahrouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sally T. Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marianne A. Mahrouse.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moussa, B.A., Hashem, H.M.A., Mahrouse, M.A. et al. Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics. Chromatographia 81, 139–156 (2018). https://doi.org/10.1007/s10337-017-3425-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-017-3425-9

Keywords

Search

Navigation